Alopecia areata is an autoimmune disorder where the immune system attacks hair follicles, leading to patchy or complete hair loss. About 700,000 people in the United States live with alopecia areata. Currently, treatment options are limited, with oral JAK inhibitors such as Eli Lilly/Incyte's Olumiant, Pfizer's Litfulo, and Sun Pharma's Leqselvi. Despite these advances, a significant unmet need remains due to the restricted number of effective treatments, the possibility of disease relapse after discontinuing therapy, and concerns about the safety of long-term use.
The stock we are bringing to your attention today is that of Q32 Bio Inc. (QTTB), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.
For comments and feedback: editorial@rttnews.com